C4 Therapeutics, Inc. (CCCC) Balance Sheet
As of 2026-06-30 (10-Q), C4 Therapeutics, Inc. (CCCC) reported total assets of $359.4M, total liabilities of $112.1M and shareholders' equity of $247.3M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $78.6M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CCCCC4 Therapeutics, Inc.Follow CCCC — free
—
Price chart with a free account
- Market cap
- 376.5M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
| Line | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 181.7 | 76.1 | 29.8 | 126.6 | 55.5 | 74.6 | 78.6 | |
| Short-term investments | 190.0 | 233.2 | — | — | — | — | — | |
| Receivables | 4.5 | 5.7 | 1.5 | 11.8 | 3.1 | 2.4 | 1.3 | |
| Current assets | 381.0 | 325.7 | 287.6 | 271.2 | 257.8 | 258.1 | 262.9 | |
| Total assets | 400.1 | 506.8 | 430.8 | 376.5 | 349.6 | 359.1 | 359.4 | |
| Current liabilities | 43.9 | 51.2 | 44.5 | 42.8 | 45.2 | 33.0 | 48.2 | |
| Long-term debt | 10.1 | 10.8 | 9.2 | 0.0 | — | — | — | |
| Short-term debt | — | 0.0 | 2.3 | 0.0 | — | — | — | |
| Total liabilities | 119.3 | 117.2 | 141.6 | 130.3 | 133.6 | 102.5 | 112.1 | |
| Shareholders' equity | 280.8 | 389.6 | 289.2 | 246.1 | 216.0 | 256.6 | 247.3 |
USD millions · SEC XBRL
C4 Therapeutics, Inc. — questions
- How much cash does C4 Therapeutics, Inc. have?
- $78.6M in cash and cash equivalents as of 2026-06-30.
- What are C4 Therapeutics, Inc.'s total assets?
- $359.4M as of 2026-06-30.
- What is C4 Therapeutics, Inc.'s shareholders' equity?
- $247.3M as of 2026-06-30.
Every figure on this page comes from C4 Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.